
What is claimed is:

1. A compound of the formula below:



wherein

R1 is selected from: $-CH_3$ and $-CF_3$;

R2 is selected from: H, $-CH_3$, $-CH_2OCH_3$, and $-CH_2OCH_2CH_3$;

R3 is selected from: H, $-C_{1-2}$ alkyl, $-CH_2OCH_3$, $-CH_2OCH_2CH_3$;

R4 is selected from: H, halo, and $-OCH_3$;

R5 is selected from H and halo;

A is selected from: CH, C-F, C-CN, and N;

X is selected from: CH, C-F, C-OCH_3, and N; and

provided that only one of X and A is N,

or a pharmaceutically acceptable salt thereof.

~~2. A compound according to claim 1 wherein R1 is $-CH_3$.~~

~~3. A compound according to claim 1 wherein R1 is $-CF_3$.~~

2. A compound according to ~~any one of~~ claims ~~1 to 3~~ wherein R2 is selected from: H, $-CH_3$, $-CH_2OCH_3$.

~~5. A compound according to any one of claims 1 to 4 wherein R2 is H.~~

~~6. A compound according to any one of claims 1 to 5 wherein R3 is selected from: H, $-CH_3$, $-CH_2OCH_3$, and $-CH_2OCH_2CH_3$.~~

37. A compound according to ~~any one of~~ claims 1 ~~to 6~~or 2 wherein R3 is selected from: H, $-CH_2OCH_3$, and $-CH_2OCH_2CH_3$.

~~8. A compound according to any one of claims 1 to 7 wherein R3 is $-CH_2OCH_3$.~~

94. A compound according to any one of claims 1 to ~~8~~ 3 wherein R4 is selected from: H, and F.

~~10. A compound according to any one of claims 1 to 9 wherein R4 is F.~~

~~11. A compound according to any one of claims 1 to 9 wherein R5 is H.~~


~~12. A compound according to any one of claims 1 to 11 wherein A is selected from CH or C-F.~~

~~13~~5. A compound according to any one of claims 1 to ~~11~~ 4 wherein A is N.

~~14. A compound according to any one of claims 1 to 11 wherein X is C-F or N.~~

~~15~~6. A compound according to any one of claims 1 to ~~13~~ 5 wherein X is CH.

~~16~~7. A compound of the formula below:



or a pharmaceutically acceptable salt thereof.

~~17. A compound of according to any of any one of claims 1 to 16 wherein the pharmaceutically acceptable salt is a hydrogen chloride addition salt.~~

~~18~~8. A compound which is N-[(1S)-2,2,2-Trifluoro-1-{4-[({(2S)-2-[(5-fluoropyridin-2-yl)oxy]-3-methoxypropyl}amino)methyl]phenyl}ethyl] methanesulfonamide hydrochloride.

~~19~~9. A compound which is N-[(1S)-2,2,2-Trifluoro-1-{4-[({(2S)-2-[(5-fluoropyridin-2-yl)oxy]-3-ethoxypropyl}amino)methyl]phenyl}ethyl]methanesulfonamide hydrochloride salt in crystalline form characterized by an X-ray powder diffraction pattern obtained from a CuKα source (λ=1.54056 Å), which comprises peaks at:

a) 14.95°, 18.13°, and 21.14° +/- 0.2° in 2θ; or

b) 12.71°, 14.95°, 18.13°, 18.67°, 21.14°, and 27.76° +/- 0.2° in 2θ; or

c) 5.46°, 11.10°, 12.71°, 13.97°, 14.95°, 18.13°, 18.67°, 21.14°, and 27.76° +/- 0.2° in 2θ.

~~20. A composition comprising substantially pure N-[(1S)-2,2,2-Trifluoro-1-{4-[({(2S)-2-[(5-fluoropyridin-2-yl)oxy]-3-ethoxypropyl}amino)methyl]phenyl}ethyl] methanesulfonamide hydrochloride salt in crystalline form according to claim 18.~~

~~21~~10. A pharmaceutical composition comprising a compound according to any one of claims 1 to ~~19~~9 and at least one of a pharmaceutically acceptable carrier, diluent, or excipient.

~~22. A method of treating a patient in need of treatment for hypertriglyceridemia, the method comprises administering to the patient an effective amount of a pharmaceutical composition according to claim 21.~~

~~23. A method of treating a patient in need of treatment for hypertriglyceridemia, the method comprises administering to the patient an effective amount of a compound according to any one of claims 1 to 19.~~

~~24~~11. A compound according to any one of claims 1 to ~~19~~ 9 for use in therapy.

~~25~~12. A compound according to any one of claims 1 to ~~19~~ 9 for use in the treatment of hypertriglyceridemia.

~~26 Use of a compound according to any one of claims 1 to 19 in the manufacture of a medicament to treat hypertriglyceridemia.~~